Eugene R Bleecker

List of Publications by Year
in descending order

80	13,456	50170 46	56606 83
papers	citations	h-index	g-index

84	84	84	12257
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	German regional variation of acute and high oral corticosteroid use for asthma. Journal of Asthma, 2022, 59, 791-800.	0.9	5
2	Mapping geographic variability of severe uncontrolled asthma in the United States. Annals of Allergy, Asthma and Immunology, 2022, 128, 78-88.	0.5	9
3	Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 871-881.	2.5	65
4	Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. Journal of Asthma, 2021, 58, 514-522.	0.9	30
5	Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort. Npj Biofilms and Microbiomes, 2021, 7, 14.	2.9	33
6	Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment. Journal of Allergy and Clinical Immunology, 2021, 148, 266-271.e2.	1.5	22
7	Pharmacogenetic studies of long-acting beta agonist and inhaled corticosteroid responsiveness in randomised controlled trials of individuals of African descent with asthma. The Lancet Child and Adolescent Health, 2021, 5, 862-872.	2.7	10
8	Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 276-293.	2.5	182
9	Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2â€“5. Pulmonary Pharmacology and Therapeutics, 2020, 60, 101881.	1.1	8
10	Response to mepolizumab treatment is sustained across 4-weekly dosing periods. ERJ Open Research, 2020, 6, 00068-2020.	1.1	4
11	Baseline sputum eosinophilÂ+ neutrophil subgroupsâ€™ clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort. Journal of Allergy and Clinical Immunology, 2020, 146, 222-226.	1.5	25
12	Association of HLA-DRB1âˆ—09:01 with tIgE levels among African-ancestry individuals with asthma. Journal of Allergy and Clinical Immunology, 2020, 146, 147-155.	1.5	14
13	Exacerbation-prone asthma in the context of race and ancestry in Asthma Clinical Research Network trials. Journal of Allergy and Clinical Immunology, 2019, 144, 1524-1533.	1.5	23
14	ADRB2 p.Thr164Ile association with hospitalization depends upon asthma severity. Journal of Allergy and Clinical Immunology, 2019, 143, 1962-1965.e4.	1.5	3
15	Association study in African-admixed populations across the Americas recapitulates asthma risk loci in non-African populations. Nature Communications, 2019, 10, 880.	5.8	71
16	Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma . Journal of Asthma and Allergy, 2019, Volume 12, 401-413.	1.5	28
17	Assembly of a pan-genome from deep sequencing of 910 humans of African descent. Nature Genetics, 2019, 51, 30-35.	9.4	276
18	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respiratory Medicine,the, 2019, 7, 46-59.	5.2	216

#	Article	IF	Citations
19	Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. Nature Genetics, 2018, 50, 42-53.	9.4	426
20	Internet-Based Monitoring in the Severe Asthma Research Program Identifies a Subgroup of Patients With Labile Asthma Control. Chest, 2018, 153, 378-386.	0.4	6
21	Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respiratory Medicine,the, 2018, 6, 51-64.	5.2	220
22	Clinical Issues in Severe Asthma. Chest, 2018, 154, 982-983.	0.4	2
23	Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis. Nature Genetics, 2018, 50, 1072-1080.	9.4	106
24	Effects of endogenous sex hormones on lung function and symptom control in adolescents with asthma. BMC Pulmonary Medicine, 2018, 18, 58.	0.8	74
25	Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. European Respiratory Journal, 2018, 52, 1800936.	3.1	173
26	Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 545-554.e4.	2.0	210
27	Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. Journal of Clinical Investigation, 2018, 128, 997-1009.	3.9	337
28	Effects of bronchoscopy on lung function in asthmatics. Journal of Asthma, 2017, 54, 866-871.	0.9	3
29	Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. Nature Genetics, 2017, 49, 426-432.	9.4	306
30	Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2017, 5, 568-576.	5.2	99
31	Gene Expression Correlated with Severe Asthma Characteristics Reveals Heterogeneous Mechanisms of Severe Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1449-1463.	2.5	130
32	Characterisation of asthma subgroups associated with circulating YKL-40 levels. European Respiratory Journal, 2017, 50, 1700800.	3.1	48
33	Design of the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) AIR Study. BMJ Open Respiratory Research, 2017, 4, e000186.	1.2	21
34	Airway Mucin Concentration as a Marker of Chronic Bronchitis. New England Journal of Medicine, 2017, 377, 911-922.	13.9	279
35	Biomarkers for severe eosinophilic asthma. Journal of Allergy and Clinical Immunology, 2017, 140, 1509-1518.	1.5	180
36	Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respiratory Medicine,the, 2017, 5, 956-967.	5.2	211

#	Article	IF	Citations
37	No genetic association detected with mepolizumab efficacy in severe asthma. Respiratory Medicine, 2017, 132, 178-180.	1.3	23
38	Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 473-481.	2.5	101
39	Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. Journal of Allergy and Clinical Immunology, 2017, 139, 1167-1175.e2.	1.5	78
40	Variability in objective and subjective measures affects baseline values in studies of patients with COPD. PLoS ONE, 2017, 12, e0184606.	1.1	20
41	Asthma heterogeneity and severity. World Allergy Organization Journal, 2016, 9, 41.	1.6	73
42	Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine,the, 2016, 4, 549-556.	5.2	433
43	Benralizumab, an anti-interleukin-5 receptor Î± monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, The, 2016, 388, 2128-2141.	6.3	1,070
44	Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting Î²2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet, The, 2016, 388, 2115-2127.	6.3	1,050
45	A continuum of admixture in the Western Hemisphere revealed by the African Diaspora genome. Nature Communications, 2016, 7, 12522.	5.8	136
46	Expression of asthma susceptibility genes in bronchial epithelial cells and bronchial alveolar lavage in the Severe Asthma Research Program (SARP) cohort. Journal of Asthma, 2016, 53, 775-782.	0.9	23
47	Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. BMC Pulmonary Medicine, 2016, 16, 65.	0.8	18
48	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. PLoS Genetics, 2016, 12, e1006011.	1.5	88
49	Impact of Age and Sex on Outcomes and Hospital Cost of Acute Asthma in the United States, 2011-2012. PLoS ONE, 2016, 11, e0157301.	1.1	57
50	Genome-wide association study and admixture mapping reveal new loci associated with total IgE levels in Latinos. Journal of Allergy and Clinical Immunology, 2015, 135, 1502-1510.	1.5	52
51	Obstructive Sleep Apnea Risk, Asthma Burden, and Lower Airway Inflammation in Adults in the Severe Asthma Research Program (SARP) II. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 566-575.e1.	2.0	107
52	IL-6 trans-signaling increases expression of airways disease genes in airway smooth muscle. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L129-L138.	1.3	42
53	Phenotypic and genotypic association of epithelial IL1RL1Âto human TH2-like asthma. Journal of Allergy and Clinical Immunology, 2015, 135, 92-99.e10.	1.5	57
54	Asthma pharmacogenetics and the development of genetic profiles for personalized medicine. Pharmacogenomics and Personalized Medicine, 2015, 8, 9.	0.4	23

#	Article	IF	Citations
55	Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respiratory Medicine,the, 2015, 3, 367-376.	5.2	153
56	Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40. Journal of Allergy and Clinical Immunology, 2015, 136, 51-58.e10.	1.5	45
57	Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respiratory Medicine,the, 2015, 3, 849-858.	5.2	443
58	Asthma Is More Severe in Older Adults. PLoS ONE, 2015, 10, e0133490.	1.1	80
59	Clinical Implications of Having Reduced Mid Forced Expiratory Flow Rates (FEF25-75), Independently of FEV1, in Adult Patients with Asthma. PLoS ONE, 2015, 10, e0145476.	1.1	49
60	Effect of Vitamin D₃on Asthma Treatment Failures in Adults With Symptomatic Asthma and Lower Vitamin D Levels. JAMA - Journal of the American Medical Association, 2014, 311, 2083.	3.8	236
61	Genome-wide interaction studies reveal sex-specific asthma risk alleles. Human Molecular Genetics, 2014, 23, 5251-5259.	1.4	70
62	GLCCI1 rs37973 does not influence treatment response to inhaled corticosteroids in white subjects with asthma. Journal of Allergy and Clinical Immunology, 2014, 133, 587-589.	1.5	43
63	Asthma heterogeneity and severityâ€"why is comprehensive phenotyping important?. Lancet Respiratory Medicine,the, 2014, 2, 10-11.	5.2	16
64	Efficacy and safety of fluticasone furoate 100ÂÎ¼g once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial. Respiratory Medicine, 2014, 108, 41-49.	1.3	37
65	International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal, 2014, 43, 343-373.	3.1	2,898
66	Benralizumab, an anti-interleukin 5 receptor Î± monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine,the, 2014, 2, 879-890.	5.2	435
67	Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. Journal of Allergy and Clinical Immunology, 2014, 133, 1557-1563.e5.	1.5	488
68	Fluticasone Furoateâ€"Vilanterol 100-25 mcg Compared with Fluticasone Furoate 100 mcg in Asthma: A Randomized Trial. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 553-561.	2.0	40
69	Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting Î² agonist treatment in a multiethnic asthma population: a genetic study. Lancet Respiratory Medicine,the, 2014, 2, 204-213.	5.2	100
70	Asthma genetics and personalised medicine. Lancet Respiratory Medicine,the, 2014, 2, 405-415.	5.2	91
71	Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma. Npj Primary Care Respiratory Medicine, 2014, 24, 14019.	1.1	23
72	Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. Journal of Allergy and Clinical Immunology, 2013, 132, 72-80.e12.	1.5	224

#	Article	IF	Citations
73	Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma. Chest, 2013, 144, 1222-1229.	0.4	86
74	Characteristics of Perimenstrual Asthma and Its Relation to Asthma Severity and Control. Chest, 2013, 143, 984-992.	0.4	78
75	ADRB2 Polymorphisms and Budesonide/Formoterol Responses in COPD. Chest, 2012, 142, 320-328.	0.4	30
76	Effect of ADRB2 polymorphisms on response to longacting Î²2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet, The, 2007, 370, 2118-2125.	6.3	222
77	Salmeterol response is not affected by Î²2-adrenergic receptor genotype in subjects with persistent asthma. Journal of Allergy and Clinical Immunology, 2006, 118, 809-816.	1.5	147
78	Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. International Journal of Cancer, 2001, 95, 354-359.	2.3	48
79	Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. Human Genetics, 2001, 108, 430-435.	1.8	53
80	Estrogen Receptor Polymorphisms Associated With Enhanced Response of HDL to Estrogen Replacement Therapy in Postmenopausal Women. Circulation, 2001, 103, 1353-1353.	1.6	2